Chromogenix, One-Stage Clotting Assays OK With Genetics Institute ReFacto
This article was originally published in The Gray Sheet
Executive SummaryClinicians may use either a one-stage clotting assay or a chromogenic substrate assay with Genetics Institute's ReFacto provided that the dose of the recombinant Factor VIII product is adjusted to reflect the lower results obtained with the former, FDA's Blood Products Advisory Committee agreed at its Dec. 11 meeting.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.